Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.

Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, Lee K, Kaang BK.

Mol Brain. 2016 May 23;9(1):56. doi: 10.1186/s13041-016-0222-6.

2.

Structural Basis of the Interaction between Tuberous Sclerosis Complex 1 (TSC1) and Tre2-Bub2-Cdc16 Domain Family Member 7 (TBC1D7).

Qin J, Wang Z, Hoogeveen-Westerveld M, Shen G, Gong W, Nellist M, Xu W.

J Biol Chem. 2016 Apr 15;291(16):8591-601. doi: 10.1074/jbc.M115.701870. Epub 2016 Feb 18.

PMID:
26893383
3.

The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.

Enriquez-Barreto L, Morales M.

Mol Cell Ther. 2016 Feb 11;4:2. doi: 10.1186/s40591-016-0047-9. eCollection 2016. Review.

4.

Familial syndromes associated with neuroendocrine tumours.

Gut P, Komarowska H, Czarnywojtek A, Waligórska-Stachura J, Bączyk M, Ziemnicka K, Fischbach J, Wrotkowska E, Ruchała M.

Contemp Oncol (Pozn). 2015;19(3):176-83. doi: 10.5114/wo.2015.52710. Epub 2015 Jul 8. Review.

5.

A novel mouse model of tuberous sclerosis complex (TSC): eye-specific Tsc1-ablation disrupts visual-pathway development.

Jones I, Hägglund AC, Törnqvist G, Nord C, Ahlgren U, Carlsson L.

Dis Model Mech. 2015 Dec;8(12):1517-29. doi: 10.1242/dmm.021972. Epub 2015 Oct 8.

6.

AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.

Agarwal S, Bell CM, Rothbart SB, Moran RG.

J Biol Chem. 2015 Nov 13;290(46):27473-86. doi: 10.1074/jbc.M115.665133. Epub 2015 Sep 21.

PMID:
26391395
7.

p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.

Agarwal S, Bell CM, Taylor SM, Moran RG.

Mol Cancer Res. 2016 Jan;14(1):66-77. doi: 10.1158/1541-7786.MCR-15-0159. Epub 2015 Sep 18.

PMID:
26385560
8.

Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Gao Y, Gartenhaus RB, Lapidus RG, Hussain A, Zhang Y, Wang X, Dan HC.

Mol Cancer Res. 2015 Dec;13(12):1602-14. doi: 10.1158/1541-7786.MCR-15-0213. Epub 2015 Sep 15.

PMID:
26374334
9.

Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi.

Housden BE, Valvezan AJ, Kelley C, Sopko R, Hu Y, Roesel C, Lin S, Buckner M, Tao R, Yilmazel B, Mohr SE, Manning BD, Perrimon N.

Sci Signal. 2015 Sep 8;8(393):rs9. doi: 10.1126/scisignal.aab3729.

10.

Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Ng HY, Oliver BG, Burgess JK, Krymskaya VP, Black JL, Moir LM.

J Cell Mol Med. 2015 Nov;19(11):2633-46. doi: 10.1111/jcmm.12593. Epub 2015 Aug 18.

11.

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.

Sasongko TH, Ismail NF, Nik Abdul Malik NM, Zabidi-Hussin ZA.

Orphanet J Rare Dis. 2015 Aug 12;10:95. doi: 10.1186/s13023-015-0317-7. Review.

12.

Impaired Reelin-Dab1 Signaling Contributes to Neuronal Migration Deficits of Tuberous Sclerosis Complex.

Moon UY, Park JY, Park R, Cho JY, Hughes LJ, McKenna J 3rd, Goetzl L, Cho SH, Crino PB, Gambello MJ, Kim S.

Cell Rep. 2015 Aug 11;12(6):965-78. doi: 10.1016/j.celrep.2015.07.013. Epub 2015 Jul 30.

13.

Activating the translational repressor 4E-BP or reducing S6K-GSK3β activity prevents accelerated axon growth induced by hyperactive mTOR in vivo.

Gong X, Zhang L, Huang T, Lin TV, Miyares L, Wen J, Hsieh L, Bordey A.

Hum Mol Genet. 2015 Oct 15;24(20):5746-58. doi: 10.1093/hmg/ddv295. Epub 2015 Jul 28.

PMID:
26220974
14.

Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.

Bai Y, Xuan B, Liu H, Zhong J, Yu D, Qian Z.

J Virol. 2015 Aug;89(15):7625-35. doi: 10.1128/JVI.01027-15. Epub 2015 May 13.

15.

Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.

Fang F, Sun S, Wang L, Guan JL, Giovannini M, Zhu Y, Liu F.

J Bone Miner Res. 2015 Jul;30(7):1195-205. doi: 10.1002/jbmr.2447.

16.

Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist.

de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M, Jansen A.

Pediatr Neurol. 2015 Jan;52(1):25-35. doi: 10.1016/j.pediatrneurol.2014.10.004. Epub 2014 Oct 16.

17.

Regulation of T cells by mTOR: the known knowns and the known unknowns.

Pollizzi KN, Powell JD.

Trends Immunol. 2015 Jan;36(1):13-20. doi: 10.1016/j.it.2014.11.005. Epub 2014 Dec 16. Review.

18.

MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR.

Zhang L, Bartley CM, Gong X, Hsieh LS, Lin TV, Feliciano DM, Bordey A.

Neuron. 2014 Oct 1;84(1):78-91. doi: 10.1016/j.neuron.2014.09.009.

19.

mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse.

Neasta J, Barak S, Hamida SB, Ron D.

J Neurochem. 2014 Jul;130(2):172-84. doi: 10.1111/jnc.12725. Epub 2014 Apr 19. Review.

20.

Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.

Pilipow K, Basso V, Migone N, Mondino A.

PLoS One. 2014 Mar 14;9(3):e91952. doi: 10.1371/journal.pone.0091952. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk